Resistance to venetoclax-induced apoptosis of CLL cells due to CD40 stimulation can be reversed by BCL-XL inhibition by Zhuang, Jack et al.
Resistance to venetoclax-induced apoptosis of CLL cells due to CD40 stimulation can be 
reversed by BCL-XL inhibition 
Teifion Luckett, Xiang Cheng, Melanie Oates, Shankar Varadarajan, Andrew R Pettitt and Jack 
Zhuang 
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, 
University of Liverpool, Liverpool, UK  
Abstract 
Dependence on anti-apoptotic protein BCL-2 for prolonged survival, a well-known feature of 
circulating chronic lymphocytic leukaemia (CLL) cells, makes BCL-2 an ideal target for 
therapeutic intervention. Consequently, venetoclax (also known as ABT-199), a small molecule 
inhibitor disrupting the interaction of BCL-2 with apoptotic BH3-only proteins, has been 
successfully developed (Souers et al, 2013), and demonstrates impressive clinical activity in 
CLL (Roberts et al, 2016). However, recent studies show that venetoclax is less effective in 
killing CLL cells that are exposed to pro-survival stimuli present in the CLL microenvironment. 
Interaction of CLL cells with non-malignant T cells in the bone marrow and lymph nodes 
constitutes an essential part of the CLL microenvironment in vivo (Burger, 2011; Caligaris-
Cappio et al, 2014). One of the most important molecular modulators mediating pro-survival 
effects is stimulation of CD40 on CLL cells by CD40 ligand (CD40L, also known as CD154) on T 
cells (Schattner, 2000; Granziero et al, 2001; Ghia et al, 2002). The CD40 stimulation can be 
replicated in vitro using a co-culture system where CLL cells are cultured on a monolayer of 
transfected murine fibroblasts expressing human CD154. We and others have shown that such 
co-culture protected CLL cells from both spontaneous apoptosis and apoptosis induced by 
cytotoxic agents that activate either mitochondrial (intrinsic) or death receptor-mediated 
(extrinsic) apoptosis pathways (Kitada et al, 1999; Granziero et al, 2001; Vogler et al, 2009; 
Pascutti et al, 2013; Zhuang et al, 2014; Chapman et al, 2017). More recently, it has been 
shown that co-culture of CLL cells with CD154-expressing fibroblasts renders them highly 
resistant to venetoclax-induced apoptosis, most likely as a result of upregulation of other anti-
apoptotic members of BCL-2 family proteins including MCL-1 and BCL-XL (Thijssen et al, 2015; 
Bojarczuk et al, 2016). Therefore, the efficacy of venetoclax might be further enhanced by 
strategies to overcome the cytoprotective effect of CD40 stimulation. 
This study thus set out to investigate whether pharmacological inhibition of MCL-1 or BCL-XL 
can restore the sensitivity of CD40-stimulated CLL cells to venetoclax and, if so, what the 
underlying mechanisms are. CD40 stimulation significantly reduced the sensitivity of primary 
CLL cells to venetoclax-induced apoptosis. This reduction correlated with increased expression 
of MCL-1 and BCL-XL in CD40-stimulated CLL cells. To target MCL-1 and BCL-XL, we used 
two novel small molecule inhibitors S63845 and A-1331852 that selectively inhibit MCL-1 
(Kotschy et al, 2016) and BCL-XL (Leverson et al, 2015), respectively. We showed that neither 
S63845 nor A-1331852 alone was effective in killing CD40-stimulated CLL cells. Moreover, 
addition of the MCL-1 inhibitor did not restore sensitivity of CD40-stimulated CLL cells to 
venetoclax. In contrast, the BCL-XL inhibitor significantly sensitised CD40-stimulated CLL cells 
to cell death induced by venetoclax. Mechanistically, we showed that BCL-XL inhibitor mediated 
sensitisation effect by blocking the binding of BH3-only protein BIM to BCL-XL in these cells. 
Finally, we showed that BIM was required for the induction of apoptosis by venetoclax as 
knockdown of BIM expression by siRNA reduced the level of apoptosis induced by venetoclax. 
Taken together, our data provide proof of concept that CD40-mediated resistance to venetoclax-
induced apoptosis of CLL cells can be overcome by combining venetoclax with an inhibitor of 
BCL-XL. 
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